Figure 1From: Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response Effect of disease characteristics on the efficacy of donepezil 23 mg/d or 10 mg/d measured by LS mean change in SIB score from baseline to Week 24. A. Functional level. B. Severity, MMSE 0-9 or 10-20. C. Severity, MMSE 0-16 or 17-20.Back to article page